UroGen Pharma Ltd. Ordinary Shares
URGN
URGN: UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
moreShow URGN Financials
Recent trades of URGN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by URGN's directors and management
Government lobbying spending instances
-
$30,000 Jul 20, 2023 Issue: Health Issues
-
$30,000 Apr 20, 2023 Issue: Health Issues
-
$60,000 Jan 20, 2023 Issue: Health Issues
-
$60,000 Oct 20, 2022 Issue: Health Issues
-
$20,000 Jul 20, 2022 Issue: Health Issues
-
$40,000 Jul 18, 2022 Issue: Health Issues
-
$40,000 Apr 15, 2022 Issue: Health Issues
-
$40,000 Jan 15, 2022 Issue: Health Issues
-
$40,000 Oct 18, 2021 Issue: Health Issues
-
$40,000 Jul 16, 2021 Issue: Health Issues
-
$40,000 Apr 17, 2021 Issue: Health Issues
-
$40,000 Jan 15, 2021 Issue: Health Issues
-
$40,000 Oct 19, 2020 Issue: Health Issues
-
$40,000 Jul 12, 2020 Issue: Health Issues
-
$40,000 Apr 20, 2020 Issue: Health Issues
New patents grants
-
Patent Title: Connectable catheter May. 04, 2021
-
Patent Title: Immunomodulating treatments of body cavities Sep. 01, 2020
-
Patent Title: Material and method for treating internal cavities Nov. 12, 2019
-
Patent Title: Material and method for treating internal cavities Aug. 07, 2018
-
Patent Title: Material and method for treating internal cavities Apr. 24, 2018
-
Patent Title: Methods for treatment of bladder cancer Feb. 06, 2018
-
Patent Title: Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer Oct. 31, 2017
-
Patent Title: Phospholipid drug analogs Jan. 10, 2017
Federal grants, loans, and purchases
- $97,430 2023-06-22 00:00:00 Agency: Department of Veterans Affairs
- $194,860 2023-06-09 00:00:00 Agency: Department of Veterans Affairs
- $97,430 2023-06-07 00:00:00 Agency: Department of Veterans Affairs
- $0 2021-02-26 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2020-12-16 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $0 2020-10-01 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Followers on URGN's company Twitter account
Number of mentions of URGN in WallStreetBets Daily Discussion
Recent insights relating to URGN
Recent picks made for URGN stock on CNBC
ETFs with the largest estimated holdings in URGN
Flights by private jets registered to URGN